CDK12 and breast carcinoma: These observations suggest that the subset of HER2-amplified breast cancers harbouring a disruption of CDK12 through somatic rearrangements may benefit from treatment with PARP inhibitors, and provide a molecular rationale for the testing of these agents in HER2-positive disease.